TACI

TACI Molekülinformation

Englischer Name	Tumor necrosis factor receptor superfamily member 13B	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	0	Target-Alias	Transmembrane activator and CAML interactor，CD267，TACI
Höchste Forschungs- und Entwicklungsphase	Preclinical

Englischer Name	Tumor necrosis factor receptor superfamily member 13B
Target-Alias	Transmembrane activator and CAML interactor，CD267，TACI
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	0
Höchste Forschungs- und Entwicklungsphase	Preclinical

TACI Produktliste

Attribut
Protein (6)Cell (1)
Produktbibliothek
Online (7)
Spezies
Human (7)
Etikett
Fc Tag & Avi Tag (1)Fc Tag (2)His Tag (1)- (2)His Tag & Avi Tag (1)
Marker
Biotin-labeled (3)Unconjugated (3)- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT TAI-H52H3	Human	HEK293	Human TACI / TNFRSF13B Protein, His Tag, low endotoxin	In den Warenkorb legen
CHEK-ATF197	Human	HEK293	Human TACI (Luc) HEK293 Reporter Cell	In den Warenkorb legen
TAI-H5253	Human	HEK293	Human TACI / TNFRSF13B (R119A, R122A) Protein, Fc Tag (MALS verified)	In den Warenkorb legen
TAI-H5254	Human	HEK293	Human TACI / TNFRSF13B Protein, Fc Tag (HPLC verified)	In den Warenkorb legen
TAI-H82E3	Human	HEK293	Biotinylated Human TACI / TNFRSF13B Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
TAI-H82F6	Human	HEK293	Biotinylated Human TACI / TNFRSF13B Protein, Fc,Avitag™	In den Warenkorb legen
TAL-H82F3	Human	HEK293	Biotinylated Human TACI / TNFRSF13B Protein, Fc,Avitag™ (MALS verified)	In den Warenkorb legen

Gesamtmenge7

TACI Molekülhintergrund

Transmembrane activator and CAML interactor (TACI), also known as tumor necrosis factor receptor superfamily member 13B (TNFRSF13B). It was originally discovered because of its ability to interact with calcium-modulator and cyclophilin ligand (CAML). TACI was later found to play a crucial role in humoral immunity by interacting with two members of the TNF family: BAFF and APRIL. The present study demonstrated that, in NSCLC, a proliferation-inducing ligand (APRIL), B-cell maturation antigen (BCMA)and transmembrane activator and CAML interactor (TACI) proteins are abnormally expressed by immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and western blotting. In addition, the expression of APRIL, BCMA and TACI were observed to be involved in extracellular signal-regulated kinase (ERK)1/2 activation in A549 cells.